论文部分内容阅读
目的观察紫杉醇联合吉西他滨方案治疗蒽环类耐药性晚期乳腺癌的疗效与安全性。方法2000年5月至2004年8月以本法治疗蒽环类耐药性晚期乳腺癌26例,每例均化疗2～3周期。结果26例中完全缓解3例(11.5%),部分缓解11例(42.3%),无变化8例(30.8%),疾病进展4例(15.4%),总有效率53.8%,中位生存时间18个月,中位肿瘤进展时间7个月。不良反应主要表现为骨髓抑制、肝功能损害、脱发、黏膜炎、周围神经毒性。结论紫杉醇和吉西他滨联合方案治疗蒽环类耐药性晚期乳腺癌疗效较好,毒性反应较轻,是蒽环类耐药性乳腺癌的有效解救治疗方案。
Objective To observe the efficacy and safety of paclitaxel plus gemcitabine in the treatment of advanced anthracycline-resistant breast cancer. Methods From May 2000 to August 2004, 26 cases of advanced anthracycline-resistant breast cancer were treated by this method, with 2 to 3 cycles of chemotherapy in each case. Results The complete remission was achieved in 3 of 26 (11.5%), partial remission in 11 (42.3%), no change in 8 (30.8%), disease progression in 4 (15.4%), and total effective rate of 53.8% 18 months, the median tumor progression time of 7 months. Adverse reactions mainly manifested as myelosuppression, liver damage, alopecia, mucositis, peripheral neurotoxicity. Conclusion paclitaxel and gemcitabine combination regimen is effective and effective in the treatment of advanced anthracycline-resistant breast cancer. It is an effective rescue treatment for anthracycline-resistant breast cancer.